iTeos Therapeutics Inc (OQ:ITOS)

Mar 06, 2024 07:01 am ET
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of Jill DeSimone to its...
Mar 06, 2024 07:00 am ET
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter...
Mar 05, 2024 04:30 pm ET
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced a poster presentation of preclinical data...
Mar 01, 2024 07:00 am ET
iTeos to Participate in Upcoming Investor Conferences
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate...
Jan 08, 2024 07:00 am ET
iTeos Announces 2024 Strategic Priorities and Anticipated Milestones
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates and strategic priorities...
Jan 03, 2024 07:00 am ET
iTeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and...
Nov 21, 2023 07:00 am ET
iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immune-oncology therapeutics for patients, today announced that management will participate in a...
Nov 07, 2023 07:00 am ET
iTeos Reports Third Quarter 2023 Financial Results and Provides Business Updates
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the third quarter...
Oct 11, 2023 05:55 pm ET
NCR Atleos Set to Join S&P SmallCap 600
NEW YORK, Oct. 11, 2023 /PRNewswire/ -- NCR Atleos Corp. (NYSE: NATL) will replace iTeos Therapeutics Inc. (NASD: ITOS) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 18. S&P MidCap 400 constituent NCR Corp. (NYSE: NCR) is spinning off NCR Atleos in a transaction expected to be completed on October 17. Following the spin-off, the NCR parent will have a name and symbol change to NCR Voyix Corp. (NYSE: VYX) and will remain in the S&P MidCap 400. iTeos Therapeutics is no longer representative of the small-cap market space.
Sep 06, 2023 07:00 am ET
iTeos to Participate in Upcoming Investor Conferences
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate...
Aug 08, 2023 07:00 am ET
iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the second quarter...
May 10, 2023 07:01 am ET
iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the first quarter...
Mar 15, 2023 07:00 am ET
iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter...
Feb 28, 2023 07:00 am ET
iTeos to Present at Cowen 43rd Annual Health Care Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and...
Feb 07, 2023 07:00 am ET
iTeos to Present at SVB Securities Global Biopharma Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and...
Jan 09, 2023 07:00 am ET
iTeos Provides Business Updates and Clinical Development Plans for 2023
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today outlined business updates that are anticipated to...
Jan 03, 2023 07:00 am ET
iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and...
Nov 22, 2022 07:00 am ET
iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and...
Nov 10, 2022 04:01 pm ET
iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the third quarter...
Aug 10, 2022 04:01 pm ET
iTeos Reports Second Quarter 2022 Financial Results and Provides Business Update
Enrolling patients with non-small cell lung cancer in a randomized Phase 2 trial evaluating the combination of inupadenant, an A2A receptor antagonist, with chemotherapy - Cash balance of $792MM as of June 30, 2022, expected to provide runway...
Aug 02, 2022 07:00 am ET
iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and...
May 12, 2022 04:01 pm ET
iTeos Reports First Quarter 2022 Financial Results and Provides Business Update
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of potentially differentiated immuno-oncology therapeutics for patients, today reported financial...
Apr 08, 2022 01:00 pm ET
iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of potentially differentiated immuno-oncology therapeutics for patients, today announced a presentation...
Mar 23, 2022 04:01 pm ET
iTeos Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today reported financial results...
Mar 01, 2022 07:00 am ET
iTeos to Present at the Cowen 42nd Annual Health Care Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel...
Feb 10, 2022 07:00 am ET
iTeos to Participate in Upcoming Investor Conferences in February
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel...
Jan 10, 2022 07:00 am ET
iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today provided a clinical...
Jan 03, 2022 04:01 pm ET
iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel...
Dec 31, 2021 04:44 pm ET
iTeos Therapeutics Set to Join S&P SmallCap 600
NEW YORK, Dec. 31, 2021 /PRNewswire/ -- iTeos Therapeutics Inc. (NASD: ITOS) will replace Magellan Health Inc. (NASD: MGLN) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, January 5. S&P 500 constituent Centene Corp. (NYSE: CNC) is acquiring Magellan Health in a deal expected to be completed soon pending final conditions.
Dec 09, 2021 04:01 pm ET
iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting and TIGIT Therapies Digital Summit 2021
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced the presentation of...
Nov 10, 2021 04:01 pm ET
iTeos Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today reported financial results...
Nov 03, 2021 07:00 am ET
iTeos to Report Third Quarter 2021 Financial Results on November 10, 2021
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a...
Sep 01, 2021 07:00 am ET
iTeos Therapeutics to Participate in Upcoming September Investor Conferences
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immune-oncology therapeutics for patients, today announced that company...
Aug 12, 2021 07:00 am ET
iTeos Reports Second Quarter 2021 Financial Results and Provides Business Update
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today reported financial results...
Aug 05, 2021 07:00 am ET
iTeos to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 12, 2021
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a...
Aug 03, 2021 07:00 am ET
iTeos Therapeutics to Present at Wedbush PacGrow Healthcare Conference 2021
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel...
Jul 08, 2021 10:03 am ET
iTeos Therapeutics to Present at William Blair Biotech Focus Conference 2021
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel...
Jun 14, 2021 07:00 am ET
iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations
iTeos Therapeutics (NASD: ITOS) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for...
Jun 04, 2021 09:00 am ET
iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced new clinical data...
May 26, 2021 07:00 am ET
iTeos to Present at the Jefferies Virtual Healthcare Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel...
May 26, 2021 07:00 am ET
iTeos to Present at the Jefferies Virtual Healthcare Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel...
May 13, 2021 04:01 pm ET
iTeos Reports First Quarter 2021 Financial Results and Provides Business Update
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today reported financial results...
May 06, 2021 04:01 pm ET
iTeos to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 13, 2021
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a...
May 03, 2021 04:01 pm ET
iTeos Appoints Tony Ho M.D. and Robert Iannone M.D., M.S.C.E., two Highly Accomplished R&D Executives to its Board of Directors
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced the appointment of...
Apr 10, 2021 08:30 am ET
iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, EOS-448, at the AACR Annual Meeting 2021
iTeos Therapeutics, Inc. (Nasdaq: ITOS), clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced a presentation...
Mar 24, 2021 04:45 pm ET
iTeos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today reported financial results...
Feb 23, 2021 07:00 am ET
iTeos to Present at Upcoming Investor Conferences in March
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel...
Feb 17, 2021 07:00 am ET
iTeos to Present at the 10th Annual SVB Leerink Global Healthcare Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel...
Jan 05, 2021 07:00 am ET
iTeos to Present at the 39th Annual J.P. Morgan Healthcare Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel...
Nov 23, 2020 04:01 pm ET
iTeos to Present at Piper Sandler 32nd Annual Healthcare Conference
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that management...
Nov 12, 2020 07:01 am ET
iTeos Reports Third Quarter 2020 Financial Results and Provides Business Update
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today reported financial results...
Nov 12, 2020 07:00 am ET
iTeos Appoints Matthew Roden, Ph.D. to Board of Directors
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced the appointment of...
Nov 05, 2020 04:05 pm ET
iTeos to Participate in Upcoming Investor Conferences in November
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that management...
Sep 08, 2020 04:05 pm ET
iTeos to Participate in Upcoming Investor Conferences in September
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that management...
Sep 01, 2020 05:26 pm ET
iTeos Reports Second Quarter 2020 Financial Results and Provides Business Update
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today reported financial results...
Jul 23, 2020 10:31 pm ET
iTeos Therapeutics Announces Pricing of Initial Public Offering
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced the pricing of its...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.